Safety Results for Daratumumab Combined With Carfilzomib, Lenalidomide, and Dexamethasone in Multiple Myeloma

According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.

MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.

The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.

Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.